Drugs / Tremfya
Tremfya cost
guselkumab · Johnson & Johnson. Every official price for Tremfya, side by side, with who pays it.
Short answer
Johnson & Johnson lists Tremfya at $14,566.44 per single SC injection or IV infusion, as of March 2025. Medicare Part B pays up to $66.998 per mg for Tremfya given by IV infusion or injection in a clinic (October 1, 2026 to December 31, 2026). Pharmacies paid an average of $14,620.07–$14,734.21 per pen or syringe (NADAC, Oct 21, 2026). At the FDA label dose of 100 mg at week 0, week 4, then every 8 weeks (an example), one dose (1 × 100 mg pen) comes to $14,566.44 at the list price and $14,620.07 at the average pharmacy acquisition cost. In 2024, Medicare Part D spent $619.0 million on Tremfya, an average of $13,429.83 per prescription fill before rebates (CMS). In Medicare Part D, the yearly out-of-pocket limit is $2,100 in 2026 and $2,400 in 2027.12471056
Source: FDA, Johnson & Johnson, CMS, data.medicaid.gov (NADAC) and Medicare.gov · checked Nov 15, 2026
Tremfya: the official numbers, by situation
| Price | Amount | Whose price, and who it applies to | Date |
|---|---|---|---|
| List price per single SC injection or IV infusion | $14,566.441 | Johnson & Johnson's price to wholesalers (WAC). Most people don't pay it directly. | March 2025 |
| Pharmacy cost (NADAC) one dose: 1 × 100 mg pen (FDA label dose, an example) | $14,620.074 | What pharmacies pay on average (CMS survey). Not a patient price. | Oct 21, 2026 |
| Medicare Part B payment limit per mg, Tremfya given by IV infusion or injection in a clinic | $66.9982 | What Medicare pays when the drug is paid under Part B (for example, given in a clinic). CMS lists Part B coinsurance for this code as 20%. | October 1, 2026 – December 31, 2026 |
On Medicare drug coverage: 4,690 of 5,492 Part D plans list Tremfya for 2027 (85%), and 98% of those require prior authorization, in CMS's formulary file published Oct 15, 2026.17 By year and tier
None of these is your price at the counter: that depends on how you pay. Details and sources for each number are further down.
FDA approval
- Tremfya (guselkumab) was first approved by the FDA on Jul 13, 2017, under application BLA761061.9
Every official price
| Price | Amount | What it is | Date |
|---|---|---|---|
| Maker's list price (WAC) | $14,566.441 | Per single SC injection or IV infusion. The price the maker charges wholesalers; most people do not pay it directly. | March 2025 (checked Oct 22, 2026) |
| Medicare Part B payment limit Tremfya given by IV infusion or injection in a clinic (guselkumab) · HCPCS J1628 | $66.9982 | Per 1 mg, when given in a clinic or hospital outpatient setting and paid under Part B. CMS lists Part B coinsurance for this code as 20%. | October 1, 2026 – December 31, 2026 |
| Pharmacy acquisition cost (NADAC) Tremfya 100 mg/mL one-press | $14,734.214 | Per pen or syringe ($14,734.21 per mL × 1 mL). The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Tremfya 100 mg/mL pen | $14,620.074 | Per pen or syringe ($14,620.07 per mL × 1 mL). The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Tremfya 100 mg/mL syringe | $14,728.424 | Per pen or syringe ($14,728.42 per mL × 1 mL). The national average price pharmacies pay to buy it. | Oct 21, 2026 |
| Pharmacy acquisition cost (NADAC) Tremfya 200 mg/2 mL pen | $14,652.204 | Per pen or syringe ($7,326.10 per mL × 2 mL). The national average price pharmacies pay to buy it. | Oct 21, 2026 |
These are prices the drug company, Medicare and pharmacies use. What you pay depends on your coverage; see below. CMS notes that a code's presence in its payment file does not by itself mean Medicare covers the drug.3
What Tremfya costs at the FDA label dose (example)
In the FDA label section "Plaque Psoriasis", the dose is 100 mg at week 0, week 4, then every 8 weeks.78 We use it only to show the math with official prices. It is an example, not a dosing recommendation: your dose is your doctor's decision, and other uses on the label have other doses.
100 mg pen prices: list price March 2025; NADAC effective Oct 21, 2026. FDA label version 30 (Oct 20, 2026).
| Period | At list price | At pharmacy acquisition cost (NADAC) |
|---|---|---|
| One dose 1 × 100 mg pen: 1 injection | $14,566.441 | $14,620.074 |
| First 52 weeks 7 × 100 mg pen: doses at weeks 0, 4, 12, 20, 28, 36, 44 | $101,965.081 | $102,340.494 |
How we count: list price $14,566.44 per single SC injection or IV infusion times the count; NADAC $14,620.07 per 100 mg pen (Tremfya 100 mg/mL pen) times the count. None of these is what you pay at the counter: the list price is what the maker charges wholesalers and NADAC is what pharmacies pay to buy the drug.
What Medicare spent on Tremfya in 2024
CMS publishes what Part D spent on each drug each year. Its spending is the gross drug cost, which includes what Medicare, the plan and the patient paid,11 and it does not reflect manufacturers' rebates.12 CMS lists Tremfya in 2 rows; together they come to $619.0 million over 46,093 prescription fills, $13,429.83 per fill.
Medicare Part D, calendar year 2024 (CMS Medicare Part D Spending by Drug, checked Nov 15, 2026).
| Product (as CMS lists it) | Total spending | Fills | People | Per fill | Per person |
|---|---|---|---|---|---|
| Tremfya Pen | $0.2 million10 | 14 | 12 | $16,895.9013 | $19,711.8914 |
| Tremfya*15 | $618.8 million10 | 46,079 | 10,848 | $13,428.7813 | $57,041.3514 |
These are totals and averages across everyone in Medicare who used the drug, not a price for one person. Averages per person depend on how long and how much each person used it.
Medicare Part D spending on Tremfya, 2020–2024
CMS Medicare Part D Spending by Drug, "Tremfya*" (all makers), gross cost before rebates, checked Nov 15, 2026.
| Year | Total spending | Prescription fills | People | Per fill |
|---|---|---|---|---|
| 2020 | $167.4 million18 | 14,355 | 3,469 | $11,660.92 |
| 2021 | $285.3 million18 | 23,040 | 5,687 | $12,380.71 |
| 2022 | $439.1 million18 | 33,444 | 7,918 | $13,130.15 |
| 2023 | $531.5 million18 | 38,622 | 8,945 | $13,761.51 |
| 2024 | $618.8 million18 | 46,079 | 10,848 | $13,428.78 |
How many Medicare Part D plans list Tremfya
Every Medicare drug plan in CMS's formulary file (standalone drug plans and Medicare Advantage plans with drug coverage). A plan counts when its drug list has at least one form or strength. Matched by RxNorm code and checked against the FDA NDC Directory. Plan counts, not people; to see your own plan's rules use Medicare Plan Finder.
| Plan year | Plans that list it | Prior auth. | Step therapy | Quantity limit | Lowest tier (plans) |
|---|---|---|---|---|---|
| 2026 | 4,979 of 5,49616 91% | 4,879 | 4 | 4,674 | tier 1: 142 · tier 2: 1 · tier 4: 50 · tier 5: 4,786 |
| 2027 | 4,690 of 5,49217 85% | 4,593 | 4 | 4,426 | tier 1: 107 · tier 4: 44 · tier 5: 4,539 |
Being on a plan's list is not a price: what you pay depends on the tier and your plan. Each plan can divide its tiers in different ways. What prior authorization, step therapy and tiers mean.
With Medicare
- What you pay depends on your Part D plan. The rules that apply to every Part D drug, from the deductible to the $2,400 out-of-pocket limit in 2027, Extra Help and the Medicare Prescription Payment Plan, are on one page: Part D costs · payment plan. Free one-on-one help: a SHIP counselor or 1-800-MEDICARE.
- When given in a clinic and paid under Medicare Part B, Medicare's payment is based on the limit above, and CMS lists the coinsurance as 20%.2 A Medicare Supplement (Medigap) policy or Medicare Advantage plan changes what you pay.
With commercial insurance or no insurance
- What you pay depends on your plan's copay or coinsurance. The maker lists its savings and support options here: Johnson & Johnson: TREMFYA cost support. We link to it but do not copy its terms.
Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.
Get an email when a price or rule changes
Only when an official GLP-1 self-pay price or a Medicare or Medicaid rule changes, at most once a week, with the official source for every change.
Official sources for this page (18)
“As of March 2025, the list price of TREMFYA® is $14,566.44 per single SC injection or IV infusion.”
Johnson & Johnson: Tremfya pricing (entered by hand) · as of Oct 22, 2026- CMS: Medicare Part B Payment Limit File (quarterly ASP pricing) · as of Oct 23, 2026
“The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate whether Medicare covers a drug.”
CMS: Medicare Part B Payment Limit File (quarterly ASP pricing) · as of Oct 23, 2026- data.medicaid.gov: NADAC (National Average Drug Acquisition Cost) 2026 · as of Oct 23, 2026
“Out-of-pocket limit Yearly $2,100 (in 2026).”
Medicare.gov: Medicare costs · as of Oct 23, 2026“Out-of-Pocket Threshold: $2,100 Out-of-Pocket Threshold: $2,400”
CMS: CY 2027 Medicare Advantage and Part D Rate Announcement (Table V-6) · as of Oct 23, 2026“100 mg administered by subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.”
FDA label (DailyMed): Tremfya, version 30 · as of Nov 15, 2026“Injection: 100 mg/mL in a single-dose prefilled pen (TREMFYA PEN).”
FDA label (DailyMed): Tremfya, version 30 · as of Nov 15, 2026“BLA761061 ORIG-1 approved 20170713”
FDA (Drugs@FDA via openFDA): BLA761061 · as of Nov 15, 2026“Tremfya Pen: Tot_Spndng_2024 236542.63, Tot_Clms_2024 14, Tot_Benes_2024 12; Tremfya*: Tot_Spndng_2024 618784543.17, Tot_Clms_2024 46079, Tot_Benes_2024 10848”
CMS: Medicare Part D Spending by Drug, 2024 (data.cms.gov) · as of Nov 15, 2026“Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”
CMS: Medicare Part D Spending by Drug (about the data) · as of Nov 15, 2026“The Part D spending metrics do not reflect any manufacturers' rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”
CMS: Medicare Part D Spending by Drug (about the data) · as of Nov 15, 2026“Part D drug spending divided by the number of prescription fills.”
CMS: Medicare Part D Spending by Drug data dictionary · as of Nov 15, 2026“Total Part D drug spending divided by the number of unique beneficiaries utilizing the drug during the benefit year.”
CMS: Medicare Part D Spending by Drug data dictionary · as of Nov 15, 2026“' * ' indicates that the average spending per dosage unit reflects multiple routes of administration of the drug”
CMS: Medicare Part D Spending by Drug data dictionary · as of Nov 15, 2026- CMS: 2026_20260916.zip (Part D formulary file for 2026 plans, published 2026-09-23) · as of Nov 15, 2026
- CMS: 2027_20261008.zip (Part D formulary file for 2027 plans, published 2026-10-15) · as of Nov 15, 2026
“Tremfya* | Guselkumab | Overall”
CMS: Medicare Part D Spending by Drug (data.cms.gov), 2020–2024 · as of Nov 15, 2026